抗癌耐药性的HDAC驱动机制:表观遗传学及其他方面
Martina Minisini1, Martina Mascaro1, Claudio Brancolini1
1Laboratory of Epigenomics, Department of Medicine, Università degli Studi di Udine, Udine 33100, Italy.
Cancer drug resistance (Alhambra, Calif.)
|December 3, 2024
概括
基因脱乙酶 (HDACs) 通过表观遗传修饰改变基因表达,促进癌症药物耐药性. 了解这些HDAC机制对于克服治疗挑战和预防癌症复发至关重要.
科学领域:
- 在瘤学瘤学.
- 表观遗传学 在表观遗传学中,表观遗传学是指表观遗传学.
- 分子生物学分子生物学
背景情况:
- 癌症的耐药性和复发带来了重大的临床挑战.
- 表观遗传变化,特别是基因组乙化变化,与治疗失败有关.
- 基因组脱乙酶 (HDACs) 是染色质结构和基因表达的关键调节剂.
研究的目的:
- 审查HDACs在癌症耐药性发展中的作用.
- 阐明HDACs导致治疗失败的表观遗传机制.
- 突出潜在的治疗策略,针对HDACs来克服耐药性.
主要方法:
- 对研究HDACs和癌症药物耐药性的研究进行文献综述.
- 对涉及基因组乙化和HDAC标的表观遗传机制的分析.
- 检查HDAC对基因表达的影响,包括促进剂和增强剂.
主要成果:
- HDACs通过控制素乙化和DNA可访问性来调节基因表达.
- HDACs的失调可以导致药物敏感性相关的基因的改变表达.
- HDACs的非歇斯顿点也会导致药物耐药性的发展.
结论:
- HDACs是驱动癌症药物耐药性的表观遗传变化的关键调解者.
- 准HDAC是一种有希望的策略,可以使瘤重新敏感于化疗和其他癌症治疗方法.
- 为了优化治疗干预措施,需要对HDAC功能和非歇斯顿点进行进一步的研究.
更多相关视频
08:59Looking for Driver Pathways of Acquired Resistance to Targeted Therapy: Drug Resistant Subclone Generation and Sensitivity Restoring by Gene Knock-down
Published on: December 11, 2017
7.2K
07:20Author Spotlight: Epigenetic Modifications and Metabolic Rewiring as Targets for Cancer Therapy
Published on: October 18, 2024
465
相关概念视频
Epigenetic Regulation
3.0K
Epigenetic changes alter the physical structure of the DNA without changing the genetic sequence and often regulate whether genes are turned on or off. This regulation ensures that each cell produces only proteins necessary for its function. For example, proteins that promote bone growth are not produced in muscle cells. Epigenetic mechanisms play an essential role in healthy development. Conversely, precisely regulated epigenetic mechanisms are disrupted in diseases like cancer.
X-chromosome...
X-chromosome...
3.0K
Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K
Inheritance of Chromatin Structures
6.2K
Epigenetics is the study of inherited changes in a cell's phenotype without changing the DNA sequences. It provides a form of memory for the differential gene expression pattern to maintain cell lineage, position-effect variegation, dosage compensation, and maintenance of chromatin structures such as telomeres and centromeres. For example, the structure and location of the centromere on chromosomes are epigenetically inherited. Its functionality is not dictated or ensured by the underlying...
6.2K
Histone Modification
3.4K
3.4K
Spreading of Chromatin Modifications
8.2K
The histone proteins in the nucleosomes are post-translationally modified (PTM) to increase or decrease access to DNA. The commonly observed PTMs are methylation, acetylation, phosphorylation, and ubiquitination of lysine amino acids in the histone H3 tail region. These histone modifications have specific meaning for the cell. Hence, they are called "histone code". The protein complex involved in histone modification is termed as "reader-writer" complex.
Writers
The writer...
Writers
The writer...
8.2K
Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
